Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H26N2O2 |
| Molecular Weight | 326.4326 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(C1CCCCC1)N2CC3N(CCCC4=CC=CC=C34)C(=O)C2
InChI
InChIKey=LGUDKOQUWIHXOV-UHFFFAOYSA-N
InChI=1S/C20H26N2O2/c23-19-14-21(20(24)16-8-2-1-3-9-16)13-18-17-11-5-4-7-15(17)10-6-12-22(18)19/h4-5,7,11,16,18H,1-3,6,8-10,12-14H2
| Molecular Formula | C20H26N2O2 |
| Molecular Weight | 326.4326 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Epsiprantel is a veterinary drug which is used as an antiparasitic agent. Epsiprantel in tablets (Cestex) is indicated for the removal of tapeworms in the cat (Dipylidium caninumand Taenia taeniaeformis) and dog (Dipylidium caninum and Taenia pisiformis). Epsiprantel acts directly on the tapeworm. Since it is minimally absorbed following oral administration, epsiprantel remains at the site of action within the gastrointestinal tract. Due to digestive process, tapeworm fragments or proglottids may not be readily visible in the stool. Epsiprantel is not a cholinesterase inhibitor. During the course of clinical field studies, Cestex was administered concurrently with diethylcarbamazine citrate (dogs only), anti-inflammatory agents, insecticides, and nematocides with no drug incompatibilities noted. The mechanism of action of epsiprantel appears to be similar to that of praziquantel, a drug that disrupts the regulation of calcium and other cations. Tetanic muscle contraction and paralysis occurs in the parasite, and the tegument becomes vacuolized
Approval Year
Sample Use Guides
veterinary use:
cats: 1.25 mg/lb of body weight
dogs: 2.5 mg/lb of body weight
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1780591
epsiprantel at a concentration of 10 ug ml-1 caused tegumental damage and death of protoscoleces, juveniles (seven-day-old) and adult (37-day-old) Echinococcus granulosus.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:12:43 GMT 2025
by
admin
on
Mon Mar 31 18:12:43 GMT 2025
|
| Record UNII |
0C1SPQ0FSR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QP52AA04
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
||
|
CFR |
21 CFR 520.816
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
||
|
WHO-VATC |
QP52AA54
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
24285
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | RxNorm | ||
|
72026
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | |||
|
98123-83-2
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | |||
|
0C1SPQ0FSR
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | |||
|
0C1SPQ0FSR
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | |||
|
C75217
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | |||
|
m4964
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000084576
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | |||
|
DTXSID3057858
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | |||
|
EPSIPRANTEL
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | |||
|
SUB06590MIG
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | |||
|
121654-56-6
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
SUPERSEDED | |||
|
CHEMBL64979
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY | |||
|
6103
Created by
admin on Mon Mar 31 18:12:43 GMT 2025 , Edited by admin on Mon Mar 31 18:12:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |